Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuqiao Sheng

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 27, 2023
Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responsesLongze Pan, Lijing Zhang, Wenjing Deng, et al.
Cancer Research|October 25, 2013
TRAF4 is a critical molecule for Akt activation in lung cancerWei Li, Cong Peng, Mee-Hyun Lee, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 9, 2014
Caffeic acid directly targets ERK1/2 to attenuate solar UV-induced skin carcinogenesisGe Yang, Yang Fu, Margarita Malakhova, et al.
Theranostics|October 3, 2025
Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapyXiaoke Gao, Meng Zhang, Shiyang Du, et al.
The Journal of Biological Chemistry|August 15, 2014
3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancerYuqiao Sheng, Wei Li, Feng Zhu, et al.
Oncotarget|April 30, 2016
PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenograftsYuqiao Sheng, Kangdong Liu, Qiong Wu, et al.
Life Sciences|May 21, 2023
PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumorsYangyang Liu, Rui Xue, Xixi Duan, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 27, 2023
Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responsesLongze Pan, Lijing Zhang, Wenjing Deng, et al.
Cancer Research|October 25, 2013
TRAF4 is a critical molecule for Akt activation in lung cancerWei Li, Cong Peng, Mee-Hyun Lee, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 9, 2014
Caffeic acid directly targets ERK1/2 to attenuate solar UV-induced skin carcinogenesisGe Yang, Yang Fu, Margarita Malakhova, et al.
Theranostics|October 3, 2025
Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapyXiaoke Gao, Meng Zhang, Shiyang Du, et al.
The Journal of Biological Chemistry|August 15, 2014
3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancerYuqiao Sheng, Wei Li, Feng Zhu, et al.
Oncotarget|April 30, 2016
PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenograftsYuqiao Sheng, Kangdong Liu, Qiong Wu, et al.
Life Sciences|May 21, 2023
PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumorsYangyang Liu, Rui Xue, Xixi Duan, et al.
Pageof 2